Evidence map›Paper›PMID 42023224›Full record

ArticleFrontiers in immunology2026

Relationship between antibody avidity, Fc-mediated functional activity and longevity of malaria vaccine responses in clinical trials.

Jessica L Horton, Jo-Anne Chan, Liriye Kurtovic, Linda Reiling, Gaoqian Feng, Kristina E M Persson, Jahit Sacarlal, Robin F Anders, James S McCarthy, Carlota Dobaño and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jessica L HortonBurnet Institute, Melbourne, VIC, Australia.
Jo-Anne ChanBurnet Institute, Melbourne, VIC, Australia.
Liriye KurtovicBurnet Institute, Melbourne, VIC, Australia.
Linda ReilingBurnet Institute, Melbourne, VIC, Australia.
Gaoqian FengBurnet Institute, Melbourne, VIC, Australia.
Kristina E M PerssonDepartment of Laboratory Medicine, Lund University, Lund, Sweden.
Jahit SacarlalCentro de Investigaco em Saude de Manhica, Maputo, Mozambique.
Robin F AndersDepartment of Biochemistry and Genetics, La Trobe University, Melbourne, VIC, Australia.
James S McCarthyVictorian Infectious Diseases Services, Doherty Institute, University of Melbourne, Melbourne, VIC, Australia.
Carlota DobañoISGlobal, Hospital Clınic Universitat de Barcelona, Barcelona, Catalonia, Spain.
Michelle J BoyleBurnet Institute, Melbourne, VIC, Australia.
James G BeesonBurnet Institute, Melbourne, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Advancing the development of highly efficacious and long-lasting malaria vaccines is hampered by incomplete knowledge of protective immune mechanisms and an absence of established correlates of immunity. Antibody avidity is frequently evaluated as an indicator of a high-quality or protective antibody response to vaccination. However, the importance of avidity in vaccine-induced immunity to malaria remains unclear. Methods/approach: We investigated the association between antibody avidity, Fc-mediated functional activities, and antibody longevity in two different Results: In both trials, we found that the magnitude of IgG induced by vaccination correlated strongly with antibody avidity indicating the two vaccine immunogenicity outcomes are related. Antibody avidity was not a major determinant of Fc-mediated functional activity, including complement fixation, binding of Fcγ-receptors, or opsonic phagocytosis. In analysis models, IgG magnitude was a stronger determinant of function than IgG avidity. Although avidity positively correlated with antibody functional activities, this was largely due to the confounding effect of the correlation between IgG magnitude and Fc functional activity. Additionally, we found that antibody avidity showed only a weak and antigen-specific association with antibody longevity. Similar findings in the two vaccine trials, which differed by vaccine antigen, adjuvant, and age group, suggests that these observations are likely to be generalisable and not specific to a vaccine type. Conclusion: Antibody avidity was not a better predictor of Fc-mediated functional activity than antibody magnitude and avidity was not a strong correlate of antibody longevity. These findings suggest that vaccine approaches that focus on increasing antibody avidity

Indexed as

Antibodies, ProtozoanAntibody AffinityImmunoglobulin Fc FragmentsMalaria, FalciparumMalaria VaccinesPlasmodium falciparumAdultChildClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicFemaleHumansImmunoglobulin GPhagocytosisReceptors, IgGAntibodies, ProtozoanImmunoglobulin Fc FragmentsImmunoglobulin GMalaria VaccinesReceptors, IgGaffinitychildrencomplementFc-mediated antibody functionsmalariaphagocytosisvaccines

Identifiers

PMID42023224
PMCPMC13095604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.